Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways

Psychoneuroendocrinology

Volumn 48, Issue , 2014, Pages 77-86

  Lian, Jiamei ^a,b   Huang, Xu Feng ^b,c   Pai, Nagesh ^b   Deng, Chao ^a,b,c  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

AMP activated protein kinase; Betahistine; Body weight gain; Food intake; Neuropeptide Y; Olanzapine

Indexed keywords

BETAHISTINE; HISTAMINE H1 RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA; MESSENGER RNA; NEUROPEPTIDE Y; OLANZAPINE; PROOPIOMELANOCORTIN; UNCLASSIFIED DRUG; ADENYLATE KINASE; BENZODIAZEPINE DERIVATIVE; HISTAMINE; HISTAMINE AGONIST; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; FOOD INTAKE; GENE EXPRESSION; HYPOTHALAMUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; UPREGULATION; WEIGHT GAIN; ANIMAL; DRUG EFFECTS; EATING; METABOLISM; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ADENYLATE KINASE; ADIPOSITY; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BETAHISTINE; EATING; FEMALE; HISTAMINE; HISTAMINE AGONISTS; NEUROPEPTIDE Y; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; WEIGHT GAIN;

EID: 84904898200     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2014.06.010     Document Type: Article

References (52)

1. Aravagiri M., Teper Y., Marder S.R. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm. Drug Dispos. 1999, 20:369-377.
2. Barak N. Betahistine: what's new on the agenda?. Exp. Opin. Investig. Drugs 2008, 17:795-804.
3. Barak N., Greenway F.L., Fujioka K., Aronne L.J., Kushner R.F. Effect of histaminergic manipulation on weight in obese adults: a randomized placebo controlled trial. Int. J. Obes. (Lond.) 2008, 32:1559-1565.
4. Broberger C., Johansen J., Johansson C., Schalling M., Hokfelt T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15043-15048.
5. Brown R.E., Stevens D.R., Haas H.L. The physiology of brain histamine. Prog. Neurobiol. 2001, 63:637-672.
6. Center for Drug Evaluation and Research FDA Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers 2005, U.S. FDA Center for Drug Evaluation and Research.
7. Correll C.U. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur. Psychiatry 2010, 25(Suppl. 2):S12-S21.
8. Deng C. Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol. Metab. Clin. N. Am. 2013, 42:545-563.
9. Deng C., Lian J., Pai N., Huang X.F. Reducing olanzapine-induced weight gain side-effect by betahistine: a study in the rat model. J. Psychopharmacol. 2012, 26:1279-1291.
10. Deng C., Weston-Green K., Han M., Huang X.F. Olanzapine treatment decreases the density of muscarinic M2 receptors in the dorsal vagal complex of rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:915-920.
11. 3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:1-4.
12. Fernø J., Varela L., Skrede S., Vázquez M.J., Nogueiras R., Diéguez C., Vidal-Puig A., Steen V.M., López M. Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS ONE 2011, 6.
13. Fossati A., Barone D., Benvenuti C. Binding affinity profile of betahistine and its metabolites for central histamine receptors of rodents. Pharmacol. Res. 2001, 43:389-392.
14. 1 receptor expression. Psychoneuroendocrinology 2008, 33:569-580.
15. 1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs 2013, 27:423-434.
16. 1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats. Psychoneuroendocrinology 2014, 42:153-164.
17. 3 receptor antagonist, powerfully suppresses peptide YY-induced food intake in rats. Biol. Psychiatry 1999, 45:475-481.
18. Jeck-Thole S., Wagner W. Betahistine: a retrospective synopsis of safety data. Drug Saf. 2006, 29:1049-1059.
19. Jorgensen E.A., Knigge U., Watanabe T., Warberg J., Kjaer A. Histaminergic neurons are involved in the orexigenic effect of orexin-A. Neuroendocrinology 2005, 82:70-77.
20. Kapur S., Van der Spek S.C., Brownlee B.A., Nobrega J. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 2003, 305:625-631.
21. 1 receptor-linked activation of hypothalamic AMP-kinase. Proc. Natl. Acad. Sci. 2007, 104:3456-3459.
22. Konturek P.C., Konturek J.W., Czesnikiewicz-Guzik M., Brzozowski T., Sito E., Konturek S.J. Neuro-hormonal control of food intake: basic mechanisms and clinical implications. J. Physiol. Pharmacol. 2005, 56(Suppl. 6):5-25.
23. Lacour M., van de Heyning P.H., Novotny M., Tighilet1 B. Betahistine in the treatment of Ménière's disease. Neuropsychiatr. Dis. Treat. 2007, 3:429-440.
24. Lage R., Dieguez C., Vidal-Puig A., Lopez M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol. Med. 2008, 14:539-549.
25. Lam D.D., Garfield A.S., Marston O.J., Shaw J., Heisler L.K. Brain serotonin system in the coordination of food intake and body weight. Pharmacol. Biochem. Behav. 2010, 97:84-91.
26. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
27. Lopez M., Lage R., Saha A.K., Perez-Tilve D., Vazquez M.J., Varela L., Sangiao-Alvarellos S., Tovar S., Raghay K., Rodriguez-Cuenca S., Deoliveira R.M., Castaneda T., Datta R., Dong J.Z., Culler M., Sleeman M.W., Alvarez C.V., Gallego R., Lelliott C.J., Carling D., Tschop M.H., Dieguez C., Vidal-Puig A. Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab. 2008, 7:389-399.
28. Lopez M., Varela L., Vazquez M.J., Rodriguez-Cuenca S., Gonzalez C.R., Velagapudi V.R., Morgan D.A., Schoenmakers E., Agassandian K., Lage R., Martinez de Morentin P.B., Tovar S., Nogueiras R., Carling D., Lelliott C., Gallego R., Oresic M., Chatterjee K., Saha A.K., Rahmouni K., Dieguez C., Vidal-Puig A. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat. Med. 2010, 16:1001-1008.
29. Martins P.J.F., Haas M., Obici S. Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 2010, 59:2418-2425.
30. Nasrallah Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry 2008, 13:27-35.
31. Newton S., Duman R. Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs 2007, 21:715-725.
32. Pai N., Deng C., Vella S.-L., Castle D., Huang X.-F. Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: temporally based hypothesis. Asian J. Psychiatry 2012, 5:315-318.
33. Paxinos G., Watson C. The Rat Brain in Sterotaxic Coordinates 2007, Academic Press, New York.
34. Poyurovsky M., Fuchs C., Pashinian A., Levi A., Weizman R., Weizman A. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology (Berlin) 2013, 226:615-622.
35. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2007, 22:659-661.
36. Ronnett G.V., Ramamurthy S., Kleman A.M., Landree L.E., Aja S. AMPK in the brain: its roles in energy balance and neuroprotection. J. Neurochem. 2009, 109(Suppl. 1):17-23.
37. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Lobos C.A., Kissling W., Davis J.M., Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 2010, 123:225-233.
38. Schneider E.H., Neumann D., Seifert R. Modulation of behavior by the histaminergic system: lessons from HR- and HR-deficient mice. Neurosci. Biobehav. Rev. 2014, 42:252-266.
39. Schwartz M.W., Woods S.C., Porte D., Seeley R.J., Baskin D.G. Central nervous system control of food intake. Nature 2000, 404:661-671.
40. Sejima E., Yamauchi A., Nishioku T., Koga M., Nakagama K., Dohgu S., Futagami K., Kataoka Y. A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats. Cell. Mol. Neurobiol. 2011, 31:985-989.
41. Sezlev D., Ak M., Yanik T., Kursungoz C., Akarsu S., Sutcigil L. The role of central neuropeptides in weight gain caused by olanzapine. Eur. Psychiatry 2013, 28(Suppl. 1):1.
42. Skrede S., Martins L., Berge R.K., Steen V.M., López M., Ferno J. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects. Int. J. Neuropharmacol. 2014, 17:91-104.
43. Szelag A., Trocha M., Merwid-Lad A. Betahistine inhibits food intake in rats. Pol. J. Pharmacol. 2001, 53:701-707.
44. Tauscher J., Jones C., Remington G., Zipursky R.B., Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol. Psychiatry 2002, 7:317-321.
45. Vehof J., Al Hadithy A.F.Y., Burger H., Snieder H., Risselada A.J., Wilffert B., Cohen D., Arends J., Wiersma D., Mulder H., Bruggeman R. Association between the ROBO1 gene and body mass index in patients using antipsychotics. Psychiatr. Genet. 2011, 21:202-207.
46. Weston-Green K., Huang X.-F., Deng C. Dosage response of metabolic dysfunction to olanzapine treatment in female Sprague Dawley rats. Behav. Brain Res. 2011, 217:337-346.
47. Weston-Green K., Huang X.-F., Deng C. Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav. Brain Res. 2011, 217:337-346.
48. Weston-Green K., Huang X.F., Deng C. Alterations to melanocortinergic GABAergic and cannabinoid neurotransmission associated with olanzapine. PLoS ONE 2012, 7:e33548.
49. Xu Y., Jones J.E., Kohno D., Williams K.W., Lee C.E., Choi M.J., Anderson J.G., Heisler L.K., Zigman J.M., Lowell B.B., Elmquist J.K. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 2008, 60:582-589.
50. 1 and pro-opiomelanocortin-melanocortin 4 receptors: independent regulation of food intake and energy expenditure. Peptides 2006, 27:326-332.
51. Zhang Q., Deng C., He M., Lian J., Wang H., Huang X.F. Brown Adipose Tissue Thermogenesis is Time-Dependently Downregulated by Olanzapine in Rats 2013, Obesity Society, Atlanta, USA.
52. Zhang Q., He M., Deng C., Wang H., Lian J., Huang X.F. Hypothalamic ghrelin signalling mediates olanzapine induced hyperphagia and weight gain in female rats. Int. J. Neuropsychopharmacol. 2014, 17:807-818.